[Phezam efficacy in patients with chronic cerebral ischemic disease]
- PMID: 15704481
[Phezam efficacy in patients with chronic cerebral ischemic disease]
Abstract
The efficacy of combined medication which comprised compounds with nootropic (piracetam) and vasoactive (cinnarisin) effects, was studied in patients with cerebral blood flow insufficiency. The main inclusion criterion was a diagnosis of chronic brain ischemia (CI). The study consisted of two stages: (1) a randomized comparative trial in neurological clinic (60 patients) and (2) estimation of the drug efficacy in routine practice (60 patients). The clinical examination was accompanied by neuropsychological tasks, kinetic tests and ultrasound investigation of brain vessels. At the first stage, a positive neurological and neuropsychological dynamics was found after 8 weeks of phezam treatment. Also a statistically significant positive dynamics was observed for a number of blood flow velocity parameters in the middle brain artery. In routine medical practice, a positive effect of phezam was seen after 2 months of the treatment for all but CI main symptoms and confirmed by the data of kinetic investigation. The patients reported good tolerability and convenience of the drug intake (one capsule instead of two tablets of nootropic and vasoactive drugs).
Similar articles
-
[Phezam in combined therapy of ischemic stroke].Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(2):24-6. Zh Nevrol Psikhiatr Im S S Korsakova. 2008. PMID: 18646379 Russian. No abstract available.
-
[The influence of cinnarizine and alvityl on cerebral blood flow and high nervous activity in chronic cerebral ischemia model].Zh Nevrol Psikhiatr Im S S Korsakova. 2004;104(1):52-3. Zh Nevrol Psikhiatr Im S S Korsakova. 2004. PMID: 14870694 Russian. No abstract available.
-
[Omaron in the restorative treatment of patients with chronic cerebrovascular insufficiency].Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(1):70-2. Zh Nevrol Psikhiatr Im S S Korsakova. 2010. PMID: 20443242 Russian. No abstract available.
-
Piracetam--an old drug with novel properties?Acta Pol Pharm. 2005 Sep-Oct;62(5):405-9. Acta Pol Pharm. 2005. PMID: 16459490 Review.
-
Vinpocetine. Monograph.Altern Med Rev. 2002 Jun;7(3):240-3. Altern Med Rev. 2002. PMID: 12126465 Review. No abstract available.
Cited by
-
Metabolic Enhancer Piracetam Attenuates the Translocation of Mitochondrion-Specific Proteins of Caspase-Independent Pathway, Poly [ADP-Ribose] Polymerase 1 Up-regulation and Oxidative DNA Fragmentation.Neurotox Res. 2018 Aug;34(2):198-219. doi: 10.1007/s12640-018-9878-2. Epub 2018 Mar 12. Neurotox Res. 2018. PMID: 29532444
-
Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats.Cell Mol Neurobiol. 2008 Jun;28(4):613-27. doi: 10.1007/s10571-007-9165-x. Epub 2007 Aug 21. Cell Mol Neurobiol. 2008. PMID: 17710536 Free PMC article.